摘要
N-甲基-D-天冬氨酸受体(NMDAR)属于离子型谷氨酸能受体,是由NR1、NR2和NR3三种亚基构成。近年来NMDAR已经逐渐成为中枢系统疾病(如抑郁症、神经痛、精神分裂症和阿尔兹海默症等)治疗的重要靶点,目前已有多个治疗药物处于临床试验阶段。本文主要综述NMDAR拮抗剂、激动剂及其调节剂的药物研究进展。
NMDAR belongs to ionotropic glutamate receptor and consists of three kinds of subunits, including NR1, NR2 and NR3. In recent years, NMDAR has become an important target for CNS disorders such as depression,neuropathic pain, schizophrenia and Alzheimer＇s disease. So far, several drugs have been in clinical trials. This article mainly reviews the research progresses for NMDAR antagonists, agonists and other modulators.
出处
《中国药物化学杂志》
CAS
CSCD
北大核心
2018年第1期58-70,共13页
Chinese Journal of Medicinal Chemistry
基金
国家自然科学基金面上项目(81373272)
